Rigel Pharmaceuticals (RIGL) closed at $44.46 on November 13, 2026, down 2.7% from the previous close, on volume of 149,835 shares (30-day average 240,250).
Data as of November 13, 2026.
13-Nov-2026
Rigel Pharmaceuticals Earnings Call Signals New Growth Era
TipRanks (Sat, 14-Nov 10:54 PM ET)
Rigel to Present at the Jefferies Global Healthcare Conference in London
PRNewswire (Tue, 10-Nov 8:05 AM ET)
Rigel Reports Third Quarter 2026 Financial Results
PRNewswire (Thu, 5-Nov 4:01 PM ET)
PRNewswire (Wed, 4-Nov 9:15 AM ET)
Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
PRNewswire (Thu, 29-Oct 8:05 AM ET)
PRNewswire (Mon, 19-Oct 8:05 AM ET)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PRNewswire (Fri, 2-Oct 8:05 AM ET)
Rigel to Participate in Upcoming September Investor Conferences
PRNewswire (Wed, 2-Sep 8:05 AM ET)
Rigel’s VEPPANU Approval Marks Significant Step for ESR1-Mutated Breast Cancer
Market Chameleon (Tue, 12-May 3:36 AM ET)
Rigel Delivers Record Sales and Net Income Surge in Q3 2025, Raises Revenue Guidance
Market Chameleon (Wed, 5-Nov 5:32 AM ET)
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Rigel Pharmaceuticals trades on the NASDAQ stock market under the symbol RIGL.
As of November 13, 2026, RIGL stock price declined to $44.46 with 149,835 million shares trading.
RIGL has a beta of 1.60, meaning it tends to be more sensitive to market movements. RIGL has a correlation of 0.09 to the broad based SPY ETF.
RIGL has a market cap of $837.18 million. This is considered a Small Cap stock.
Last quarter Rigel Pharmaceuticals reported $81 million in Revenue and $.65 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.29.
In the last 3 years, RIGL traded as high as $52.61 and as low as $7.48.
The top ETF exchange traded funds that RIGL belongs to (by Net Assets): AVUV, VTI, XBI, IWM, VXF.
RIGL has underperformed the market in the last year with a price return of +11.5% while the SPY ETF gained +13.4%. However, in the short term, RIGL had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.0% vs -2.8% return in SPY. But in the last 2 weeks, RIGL shares have been beat by the market, returning -13.4% compared to an SPY return of -0.2%.
RIGL support price is $44.01 and resistance is $47.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RIGL shares will trade within this expected range on the day.
